Evidence map›Paper›PMID 41526340›Full record

ArticleBlood cancer journal2026

NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance.

Huiqin Bian, Naseema Gangat, Na Shen, Jiuxia Pang, David Wald, William Tse, Ayalew Tefferi, Fei Yan, Shujun Liu

Abstract readLetter
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huiqin BianDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Naseema GangatDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-9104-6172
Na ShenKey laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China.
Jiuxia PangDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
David WaldDepartment of Pathology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-8695-1178
William TseDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.
Ayalew TefferiDivision of Hematology, Mayo Clinic, Rochester, MN, USA. tefferi.ayalew@mayo.edu.ORCID http://orcid.org/0000-0003-4605-3821
Fei YanState Key Laboratory of Inorganic Synthesis & Preparative Chemistry, College of Chemistry, Jilin University, Changchun, China. feiyan@jlu.edu.cn.
Shujun LiuDepartment of Medicine, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA. shujun.liu2@case.edu.ORCID http://orcid.org/0000-0002-5347-8345

Funding

The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemiaR01CA248019 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, SHUJUN · 2021 to 2025
$3.2M
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem CellR01CA266256 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, GANG, LIU, SHUJUN · 2022 to 2025
$3.0M
Targeting aberrant epigenetics by nanomedicineR01CA149623 · NCI · UNIVERSITY OF MINNESOTA · PI LIU, SHUJUN · 2010 to 2014
$1.8M
NCI NIH HHS R01 CA149623NCI NIH HHS R01 CA248019NCI NIH HHS R01 CA266256U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA149623U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA248019U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA266256
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41526340
PMCPMC12795839

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.